Key terms
About TCON
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TCON news
Apr 12
4:54pm ET
Tracon Pharmaceuticals files to sell common stock, warrants, no amount given
Apr 08
9:14am ET
Tracon Pharmaceuticals announces 1-for-20 reverse stock split
Apr 03
12:25pm ET
Buy Rating Affirmed for TRACON Pharmaceuticals Amid Promising Envafolimab Trial Outlook
Apr 03
12:15pm ET
Tracon Pharmaceuticals price target lowered to $3 from $6 at H.C. Wainwright
Apr 03
8:05am ET
Tracon says IDMC reccommends ENVASARC Phase 2 trial continue ‘as planned’
Mar 25
8:31am ET
Two new option listings and option delistings on March 25th
Mar 15
11:32am ET
Biotech Alert: Searches spiking for these stocks today
Mar 13
8:46am ET
JonesTrading Reaffirms Their Hold Rating on TRACON Pharmaceuticals (TCON)
Mar 11
11:13am ET
Biotech Alert: Searches spiking for these stocks today
Mar 08
10:46am ET
Biotech Alert: Searches spiking for these stocks today
Mar 07
10:35am ET
Buy Rating for TRACON Pharmaceuticals on Strong Financials and Promising Clinical Trials
Mar 07
10:29am ET
Biotech Alert: Searches spiking for these stocks today
Mar 06
6:05am ET
Tracon Pharmaceuticals price target lowered to $6 from $7 at H.C. Wainwright
Mar 05
4:13pm ET
Tracon Pharmaceuticals reports Q4 EPS 1c, consensus (8c)
Mar 05
4:13pm ET
Tracon Pharmaceuticals reports Q4 EPS 1c, consensus (8c)
No recent press releases are available for TCON
TCON Financials
Key terms
Ad Feedback
TCON Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TCON Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range